Anatomical site in vagina Timepoint | Oestrogen N; mean (SD) | No treatment N; mean (SD) | Mean difference between groups (95% CI) |
Aa (anterior wall), cm | |||
Baseline | n=49; | n=48; | |
0.1 (1.9) | −0.3 (1.7) | ||
6 months* | n=26; | n=29; | 0.7 (0.1 to 1.3) |
−1.7 (2.0) | −2.6 (2.0) | ||
Ba (anterior edge), cm | |||
Baseline | n=49; | n=48; | |
0.2 (2.0) | 0.1 (1.8) | ||
6 months* | n=25; | n=29; | 0.6 (0.0 to 1.2) |
−2.0 (2.0) | −2.9 (1.9) | ||
C (cervix/cuff), cm | |||
Baseline | n=49; | n=48; | |
−3.7 (2.5) | −3.4 (3.4) | ||
6 months* | n=25; | n=29; | −0.2 (−1.3 to 0.9) |
−2.9 (2.8) | −2.2 (3.6) | ||
Ap (posterior wall), cm | |||
Baseline | n=49; | n=48; | |
−1.2 (1.5) | −1.0 (1.7) | ||
6 months* | n=26; | n=29; | 0.5 (−0.2 to 1.1) |
−0.8 (1.7) | −1.0 (1.7) | ||
Bp (posterior edge), cm | |||
Baseline | n=49; | n=48; | |
−1.1 (1.6) | −1.0 (1.8) | ||
6 months* | n=26; | n=29; | 0.4 (−0.3 to 1.1) |
−0.9 (1.8) | −1.0 (1.8) | ||
D (posterior fornix), cm | |||
Baseline | n=39; | n=40; | |
−5.3 (1.9) | −5.1 (2.6) | ||
6 months* | n=7; | n=4; | 0.7 (−6.2 to 7.5) |
−1.3 (1.5) | −1.8 (1.9) | ||
Total vaginal length, cm | |||
Baseline | n=49; | n=48; | |
8.5 (1.1) | 8.0 (1.6) | ||
6 months† | n=26; | n=29; | 0.3 (0.4 to 0.9) |
−0.2 (1.3) | −0.5 (1.7) | ||
Objective prolapse (any of Aa, Ba, C, Ap, Bp or D >0) at 6 months | |||
N (%) | N (%) | Relative risk (95% CI)‡ | |
Failure | 26-Sep | 13/29 | 0.77 (0.40 to 1.50) |
*Change from baseline adjusted for baseline; difference <0 indicates better with oestrogen.
†Adjusted for baseline length; difference <0 indicates better with oestrogen.
‡<1 indicates less prolapse failures with oestrogen.
POP, pelvic organ prolapse; POP-Q, POP quantification system.